Thursday, November 8, 2012
Publication and contact
Assays & screens
Androgen receptor (AR) activation levels on circulating
tumor cells (CTCs) to predict response to second-line therapy in
castration-resistant prostate cancer (CRPC)
In vitro studies suggest AR activation on CTCs could help
prostate cancer prognosis. In untreated patients with human prostate cancer,
AR activation was greater on CTCs than on samples from healthy controls. CTCs
from patients that responded to first-line androgen deprivation therapy
showed activated AR phenotypes, whereas CTCs from patients with CRPC showed
both activated and inactivated AR phenotypes. In patients with CRPC, having
more than 10% CTCs with the mixed AR phenotype prior to second-line therapy
or a highly activated AR phenotype after therapy was associated with reduced
overall survival. Next steps could include confirming the findings in
Published online Nov. 8, 2012
Patent and licensing status
Miyamoto, D.T. et al.
Cancer Discov.; published online Oct. 23, 2012;
Contact: Daniel A. Haber, Massachusetts General Hospital, Charlestown,
Contact: Shyamala Maheswaran,
same affiliation as above
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]